(BSX) Boston Scientific - Ratings and Ratios
Stents, Catheters, Pacemakers, Defibrillators, Stimulators
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 21.5% |
| Value at Risk 5%th | 32.5% |
| Relative Tail Risk | -7.83% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -3.85 |
| CAGR/Max DD | 1.84 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.498 |
| Beta | 0.694 |
| Beta Downside | 0.869 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.52% |
| Mean DD | 2.79% |
| Median DD | 1.80% |
Description: BSX Boston Scientific December 02, 2025
Boston Scientific (BSX) designs, manufactures and markets a broad portfolio of interventional medical devices across two main segments-MedSurg and Cardiovascular-serving specialties such as gastroenterology, urology, neuromodulation, cardiac rhythm management, and peripheral vascular care. The company’s product slate includes endoscopic clips, biliary stents, single-use duodenoscopes, ureteral stents, holmium laser systems, spinal cord stimulators, the WATCHMAN FLX left-atrial appendage closure device, and a range of implantable cardiac monitors and defibrillators.
Key recent metrics: BSX reported FY 2023 revenue of $12.3 billion, with the Cardiovascular segment contributing roughly 55 % of total sales and delivering a 22 % operating margin, while MedSurg grew at a 7 % CAGR over the past three years driven by demand for single-use devices. R&D spending remained steady at about 7 % of revenue, supporting a pipeline that includes next-generation leadless pacing and AI-enabled remote monitoring solutions. Macro-level drivers include an aging U.S. population, rising prevalence of chronic cardiovascular disease, and a sustained shift toward minimally invasive, outpatient procedures that favor disposable device formats.
For a deeper quantitative dive, you might explore the ValueRay platform’s detailed valuation models for BSX.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (2.79b TTM) > 0 and > 6% of Revenue (6% = 1.16b TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 3.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.99% (prev 17.92%; Δ -3.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 4.63b > Net Income 2.79b (YES >=105%, WARN >=100%) |
| Net Debt (10.20b) to EBITDA (4.68b) ratio: 2.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.50b) change vs 12m ago 0.54% (target <= -2.0% for YES) |
| Gross Margin 65.05% (prev 62.41%; Δ 2.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 47.90% (prev 41.78%; Δ 6.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.57 (EBITDA TTM 4.68b / Interest Expense TTM 403.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.50
| (A) 0.06 = (Total Current Assets 8.04b - Total Current Liabilities 5.33b) / Total Assets 42.71b |
| (B) 0.11 = Retained Earnings (Balance) 4.90b / Total Assets 42.71b |
| (C) 0.07 = EBIT TTM 2.65b / Avg Total Assets 40.39b |
| (D) 0.26 = Book Value of Equity 4.90b / Total Liabilities 19.08b |
| Total Rating: 1.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.59
| 1. Piotroski 8.50pt |
| 2. FCF Yield 2.31% |
| 3. FCF Margin 19.15% |
| 4. Debt/Equity 0.48 |
| 5. Debt/Ebitda 2.18 |
| 6. ROIC - WACC (= -1.69)% |
| 7. RoE 12.42% |
| 8. Rev. Trend 97.92% |
| 9. EPS Trend 96.84% |
What is the price of BSX shares?
Over the past week, the price has changed by -3.46%, over one month by -2.50%, over three months by -9.82% and over the past year by +9.92%.
Is BSX a buy, sell or hold?
- Strong Buy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BSX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 126.5 | 29.7% |
| Analysts Target Price | 126.5 | 29.7% |
| ValueRay Target Price | 118.7 | 21.7% |
BSX Fundamental Data Overview December 02, 2025
P/E Trailing = 54.3209
P/E Forward = 29.3255
P/S = 7.7826
P/B = 6.4367
P/EG = 0.9935
Beta = 0.674
Revenue TTM = 19.35b USD
EBIT TTM = 2.65b USD
EBITDA TTM = 4.68b USD
Long Term Debt = 10.99b USD (from longTermDebt, last quarter)
Short Term Debt = 483.0m USD (from shortLongTermDebt, last quarter)
Debt = 11.15b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 10.20b USD (from netDebt column, last quarter)
Enterprise Value = 160.46b USD (150.59b + Debt 11.15b - CCE 1.27b)
Interest Coverage Ratio = 6.57 (Ebit TTM 2.65b / Interest Expense TTM 403.0m)
FCF Yield = 2.31% (FCF TTM 3.71b / Enterprise Value 160.46b)
FCF Margin = 19.15% (FCF TTM 3.71b / Revenue TTM 19.35b)
Net Margin = 14.41% (Net Income TTM 2.79b / Revenue TTM 19.35b)
Gross Margin = 65.05% ((Revenue TTM 19.35b - Cost of Revenue TTM 6.76b) / Revenue TTM)
Gross Margin QoQ = 69.93% (prev 67.65%)
Tobins Q-Ratio = 3.76 (Enterprise Value 160.46b / Total Assets 42.71b)
Interest Expense / Debt = 0.78% (Interest Expense 87.0m / Debt 11.15b)
Taxrate = 19.49% (183.0m / 939.0m)
NOPAT = 2.13b (EBIT 2.65b * (1 - 19.49%))
Current Ratio = 1.51 (Total Current Assets 8.04b / Total Current Liabilities 5.33b)
Debt / Equity = 0.48 (Debt 11.15b / totalStockholderEquity, last quarter 23.39b)
Debt / EBITDA = 2.18 (Net Debt 10.20b / EBITDA 4.68b)
Debt / FCF = 2.75 (Net Debt 10.20b / FCF TTM 3.71b)
Total Stockholder Equity = 22.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.53% (Net Income 2.79b / Total Assets 42.71b)
RoE = 12.42% (Net Income TTM 2.79b / Total Stockholder Equity 22.45b)
RoCE = 7.91% (EBIT 2.65b / Capital Employed (Equity 22.45b + L.T.Debt 10.99b))
RoIC = 6.33% (NOPAT 2.13b / Invested Capital 33.63b)
WACC = 8.02% (E(150.59b)/V(161.73b) * Re(8.57%) + D(11.15b)/V(161.73b) * Rd(0.78%) * (1-Tc(0.19)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 79.75% ; FCFE base≈3.01b ; Y1≈3.71b ; Y5≈6.33b
Fair Price DCF = 65.67 (DCF Value 97.35b / Shares Outstanding 1.48b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 96.84 | EPS CAGR: 14.59% | SUE: 2.12 | # QB: 11
Revenue Correlation: 97.92 | Revenue CAGR: 13.72% | SUE: 2.10 | # QB: 8
EPS next Quarter (2026-03-31): EPS=0.79 | Chg30d=+0.008 | Revisions Net=+8 | Analysts=20
EPS next Year (2026-12-31): EPS=3.47 | Chg30d=+0.058 | Revisions Net=+29 | Growth EPS=+14.2% | Growth Revenue=+11.4%
Additional Sources for BSX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle